Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5670)
All Articles published online
|
Publishing Process of This Article
|
Jul 6, 2022 (publication date) through Dec 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Hao YY, Chen PP, Yuan XG, Zhao AQ, Liang Y, Liu H, Qian WB. Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. World J Clin Cases 2022; 10(19): 6555-6562 [PMID: 35979312 DOI: 10.12998/wjcc.v10.i19.6555] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Hao YY, Chen PP, Yuan XG, Zhao AQ, Liang Y, Liu H, Qian WB. Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. World J Clin Cases 2022; 10(19): 6555-6562 [PMID: 35979312 DOI: 10.12998/wjcc.v10.i19.6555] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i19/6555.htm |
| Number | Citing Articles |
| 1 |
Zhenhao Wang, Hao Xu, Yu Mei, Min Xiao, Yang Cao, Liang Huang, Zhuming Yang, Yicheng Zhang, Zhiqiang Han, Miao Zheng, Zhenya Hong. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy. International Immunopharmacology 2024; 133: 112014 doi: 10.1016/j.intimp.2024.112014
|
| 2 |
Fen Zhang, Yu Chen, Qian Cui, Yan Ge, Yanhui Liu. Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-024-00991-5
|
| 3 |
Jaromir Tomasik, Dominik Bilicki, Grzegorz Władysław Basak. Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients. Expert Opinion on Biological Therapy 2024; 24(5): 389 doi: 10.1080/14712598.2024.2354371
|
| 4 |
Rubing Zheng, Xiaojian Zhu, Yi Xiao. Overcoming CAR-T bottlenecks in high-risk DLBCL: a molecular subtyping enhancement strategy. Cancer Cell International 2025; 25(1) doi: 10.1186/s12935-025-04046-9
|
| 5 |
Zhao Liang, Yang Liu, Ping Li, Aiqi Zhao, Honghao Zhang, Cuiying Pang, Shiqi Chen, Bin Xue, Zhifang Li, Wenbin Qian, Aibin Liang, Weidong Han, Yuhua Li. A multicenter retrospective study of HDAC inhibitor- based regimen for relapsed/refractory non-hodgkin lymphoma patients post CAR-T therapy. Immunity & Inflammation 2025; 1(1) doi: 10.1007/s44466-025-00010-4
|
| 6 |
Wenxin Jiang, Tingyu Wen, Peng Liu. Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis. PeerJ 2025; 13: e20314 doi: 10.7717/peerj.20314
|
| 7 |
|
| 8 |
Chen-Xu Ni, Yu Zhao, Hong Qian, Hui Fu, Yu-Ying Yan, Yu-Shuang Qiu, Can-Can Zhou, Fang Huang, Fu-Ming Shen, Dong-Jie Li, Qing Xu. Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1121122
|
| 9 |
Fatemeh Hedayat, Elnaz Faghfuri. Harnessing histone deacetylase inhibitors for enhanced cancer immunotherapy. European Journal of Pharmacology 2025; 997: 177620 doi: 10.1016/j.ejphar.2025.177620
|